LETTERS TO THE EDITOR Lag time for children with brain tumours
We read with considerable interest the paper by Edgeworth et al highlighting the failure of physicians to recognise often vague symptoms and/or signs as markers of serious disease, especially childhood brain tumours. ' We previously studied the time interval (designated lag time) between the first symptom and/or signs and confirmed diagnosis in an unselected cohort of children with cancer including 28 with brain tumours, and found that for brain tumours the lag time of 13 weeks far exceeded the interval for all other tumours2 (5 weeks for acute lymphoblastic leukaemia, bone tumours 8.4 weeks, nephroblastoma 2.8 weeks). There duce a tremendous amount of parent and patient anxiety let alone resentment. Ongoing medical education must be programmed to try to prevent such delays. However, for the majority of children the other components, namely the time from first symptom or sign to when medical advice is sought, and the time to get through the system and receive appropriate treatment, which appear to be essentially related to inherent tumour characteristics and health care provision respectively, together make the major contribution to length of lag time. We are conducting a prospective study attempting tO clarify the contribution of each of these components to the overall lag time. From all the published work to date the greatest contribution does appear to be related to inherent tumour characteristics which in turn determine the mode of presentation. Before parents blame themselves or doctors for delayed diagnosis we need to emphasise these other aspects of tumour presentation. 
Is microalbuminuria progressive?
We read with interest the article by Shields et al on the question whether microalbuminuria is progressive or not.' Our data, presented at the 21th Annual Meeting of the ISPAD in Linkoping,2 are fully in line with the conclusions of this work. In 1984 we indentified 14 children and adolescents as having persistent microalbuminuria (urinary albumin excretion (UAE) 30-300 mg/day) with insulin dependent diabetes mellitus (median age = 15.2 years; median duration of diabetes = 5.7 years). Eight cases showed HLA DR3-DR4. A regular follow up for six years of these microalbuminuric patients allowed us to follow their progress: two developed macroalbuminuria, five remained microalbuminuric without -presenting a significant increase in UAE, and seven reverted stably to normal, after a period ofmicroalbuminuria of between 1 and 5.5 years. These latter patients did not differ from those remaining microalbuminuric either as regards degree of metabolic control or UAE levels during follow up, whereas they did differ as regards a higher prevalence (6/7) of cases with onset of diabetes in peripubertal age. Shield et al did not report data regarding age or pubertal stage of the single microalbuminuric patients; we feel this finding could be important in that it could be the pubertal factor which differentiates the natural history for microalbuminuria in childhood from that of adulthood. Puberty, with its important hormonal changes, could in fact act as 'exercise test' for the kidney of predisposed subjects; this would lead to a deterioration which, limited to the pubertal period, would be temporary. Supporting this hypothesis is the fact that six of our 10 patients (all females) with intermittent microalbuminuria, occurring at the beginning of puberty, reverted to normal at the end of puberty itself, that is after menarche.
The predictive value for later overt nephropathy of microalbuminuria is therefore poor among children and young adults and this possible spontaneous normalisation of microalbuminuria should be taken into account when evaluating the effects of interventional drug treatment in patients of this age. This report is now the third to challenge the predictive value of microalbuminuria defined as 20-200 jg/min (30-300 mg/day) in childhood and adolescence as a recent article from Rudberg and Dahlquist reached similar conclusions.3 The implications of microalbuminuria in this age group need to be addressed prospectively in a large cohort of patients before embarking on either routine clinical screening or interventional trials. A study (microalbuminuria in diabetic adolescents and children, MIDAC), currently in the pilot stage, will address the prevalence and progression of abnormal albumin excretion in approximately 2000 patients and its relationship with glycaemic control, blood pressure, and pubertal status which we agree may be of importance in defining the longer term implications of microalbuminuria. 
